Lisata Therapeutics Management
Management criteria checks 2/4
Lisata Therapeutics' CEO is Dave Mazzo, appointed in Jan 2015, has a tenure of 9.25 years. total yearly compensation is $1.93M, comprised of 33.7% salary and 66.3% bonuses, including company stock and options. directly owns 2.1% of the company’s shares, worth $506.80K. The average tenure of the management team and the board of directors is 3.5 years and 8.4 years respectively.
Key information
Dave Mazzo
Chief executive officer
US$1.9m
Total compensation
| CEO salary percentage | 33.7% |
| CEO tenure | 9.3yrs |
| CEO ownership | 2.1% |
| Management average tenure | 3.5yrs |
| Board average tenure | 8.4yrs |
Recent management updates
Recent updates
Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?
Mar 22
We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully
Sep 15Caladrius rallies on approval of merger, name change to Lisata Therapeutics
Sep 14Caladrius Biosciences GAAP EPS of -$0.11 beats by $0.01
Aug 04We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully
May 02We're Keeping An Eye On Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Rate
Jan 05Companies Like Caladrius Biosciences (NASDAQ:CLBS) Are In A Position To Invest In Growth
May 09Caladrius suspends CLBS119 COVID-19 study
Dec 14Here's Why We're Not Too Worried About Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Situation
Nov 30
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$21m |
| Sep 30 2023 | n/a | n/a | -US$21m |
| Jun 30 2023 | n/a | n/a | -US$54m |
| Mar 31 2023 | n/a | n/a | -US$56m |
| Dec 31 2022 | US$2m | US$650k | -US$54m |
| Sep 30 2022 | n/a | n/a | -US$55m |
| Jun 30 2022 | n/a | n/a | -US$25m |
| Mar 31 2022 | n/a | n/a | -US$24m |
| Dec 31 2021 | US$1m | US$631k | -US$27m |
| Sep 30 2021 | n/a | n/a | -US$26m |
| Jun 30 2021 | n/a | n/a | -US$25m |
| Mar 31 2021 | n/a | n/a | -US$12m |
| Dec 31 2020 | US$1m | US$613k | -US$8m |
| Sep 30 2020 | n/a | n/a | -US$8m |
| Jun 30 2020 | n/a | n/a | -US$7m |
| Mar 31 2020 | n/a | n/a | -US$19m |
| Dec 31 2019 | US$2m | US$597k | -US$19m |
| Sep 30 2019 | n/a | n/a | -US$18m |
| Jun 30 2019 | n/a | n/a | -US$17m |
| Mar 31 2019 | n/a | n/a | -US$16m |
| Dec 31 2018 | US$2m | US$594k | -US$16m |
| Sep 30 2018 | n/a | n/a | -US$17m |
| Jun 30 2018 | n/a | n/a | -US$17m |
| Mar 31 2018 | n/a | n/a | -US$14m |
| Dec 31 2017 | US$1m | US$577k | -US$16m |
Compensation vs Market: Dave's total compensation ($USD1.93M) is above average for companies of similar size in the US market ($USD673.36K).
Compensation vs Earnings: Dave's compensation has increased whilst the company is unprofitable.
CEO
Dave Mazzo (66 yo)
9.3yrs
Tenure
US$1,929,934
Compensation
Dr. David J. Mazzo, also known as Dave, B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph D., serves as Independent Non Executive Chairman at Visioneering Technologies, Inc. since February 28, 2020. He served as Lead...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 9.3yrs | US$1.93m | 2.1% $ 506.8k | |
| Executive VP of R&D and Chief Medical Officer | 2.6yrs | US$1.12m | 0.65% $ 156.7k | |
| VP of Finance & Treasury | 3.1yrs | no data | no data | |
| Vice President of Business Development & Operations and Corporate Counsel | 1.3yrs | no data | no data | |
| Chief Information Officer | 3.5yrs | no data | no data | |
| Vice President of Investor Relations & Corporate Communications | 6.3yrs | no data | no data | |
| Vice President of Human Resources | 5.3yrs | no data | no data | |
| Vice President of Global Regulatory Affairs | no data | US$400.18k | no data |
3.5yrs
Average Tenure
65yo
Average Age
Experienced Management: LSTA's management team is considered experienced (3.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 9.3yrs | US$1.93m | 2.1% $ 506.8k | |
| Independent Director | 9.8yrs | US$123.18k | 0.36% $ 87.3k | |
| Independent Chairman of the Board | 7.5yrs | US$155.86k | 0.36% $ 86.3k | |
| Independent Director | 1.6yrs | US$18.78k | 0.24% $ 58.0k | |
| Member of Type 1 Diabetes Scientific Advisory Board | no data | no data | no data | |
| Immune Modulation Program Advisor | no data | no data | no data | |
| Immune Modulation Program Advisor | no data | no data | no data | |
| Immune Modulation Program Advisor | no data | no data | no data | |
| Immune Modulation Program Advisor | no data | no data | no data | |
| Immune Modulation Program Advisor | no data | no data | no data | |
| Member of Type 1 Diabetes Scientific Advisory Board | no data | no data | no data | |
| Member of Type 1 Diabetes Scientific Advisory Board | no data | no data | no data |
8.4yrs
Average Tenure
66yo
Average Age
Experienced Board: LSTA's board of directors are considered experienced (8.4 years average tenure).